These findings along with the lack of benefit from chemotherapy in patients with MEK5-ERK5 overexpression support the rationale to inhibit MEK5-ERK5 signaling pathway in combination with neoadjuvant and/or adjuvant chemotherapy in ER-negative, TNBC and basal-like breast cancer to improve survival rates. This evidence concerns the gene MAPK7 and breast carcinoma.